Glutathione is required for efficient production of infectious picornavirus virions  by Smith, Allen D. & Dawson, Harry
6) 258–267
www.elsevier.com/locate/yviroVirology 353 (200Glutathione is required for efficient production of infectious
picornavirus virions
Allen D. Smith ⁎, Harry Dawson
Nutrient Requirements and Functions Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service,
U.S. Department of Agriculture, Beltsville, MD 20705, USA
Received 30 December 2005; returned to author for revision 31 January 2006; accepted 8 June 2006
Available online 24 July 2006Abstract
Glutathione is an intracellular reducing agent that helps maintain the redox potential of the cell and is important for immune function. The drug
L-buthionine sulfoximine (BSO) selectively inhibits glutathione synthesis. Glutathione has been reported to block replication of HIV, HSV-1, and
influenza virus, whereas cells treated with BSO exhibit increased replication of Sendai virus. Pre-treatment of HeLa cell monolayers with BSO
inhibited replication of CVB3, CVB4, and HRV14 with viral titers reduced by approximately 6, 5, and 3 log10, respectively. The addition of
glutathione ethyl ester, but not dithiothreitol or 2-mercaptoethanol, to the culture medium reversed the inhibitory effect of BSO. Viral RNA and
protein synthesis were not inhibited by BSO treatment. Fractionation of lysates from CVB3-infected BSO-treated cells on cesium chloride and
sucrose gradients revealed that empty capsids but not mature virions were being produced. The levels of the 5S and 14S assembly intermediates,
however, were not affected by BSO treatment. These results demonstrate that glutathione is important for production of mature infectious
picornavirus virions.
Published by Elsevier Inc.Keywords: Coxsackievirus B3; Picornavirus; Glutathione; ReplicationIntroduction
Oxidative stress has been implicated in the etiology of several
diseases including diabetes and cardiovascular disease. Recent
evidence has demonstrated, however, that reactive oxygen
species can act as important secondary messengers in signal
transduction pathways (Esposito et al., 2004; Hehner et al.,
2000; Pani et al., 2000). The cell has a number of mechanisms
available to control oxidative stress. These comprise several
enzymes including catalase, glutathione peroxidases, thiore-
doxin reductase, and superoxide dismutase. The cell also has a
number of lower molecular weight molecules that can act as
reactive oxygen species (ROS) scavengers, the most important
of which is the tripeptide, glutathione (GSH). Glutathione is
present at millimolar concentration in the cell (Uhlig and⁎ Corresponding author. Fax: +1 301 504 9062.
E-mail addresses: smitha@ba.ars.usda.gov (A.D. Smith),
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0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2006.06.012Wendel, 1992), is important in detoxification pathways via
glutathione transferases (Meister and Anderson, 1983), and is
critical for maintaining the redox potential of the cell. It is now
appreciated that the redox potential of the cell can influence the
activation of many genes through the induction of transcription
factors including NF-κB and AP-1 that are important for
immune function (Abate et al., 1990; Schenk et al., 1994),
antioxidant defense (Bauer and Bauer, 2002), and induction of
apoptosis (Haddad, 2002; Kwon et al., 2003).
Oxidative stress has been implicated as a possible mechan-
ism leading to selection of more virulent viral genotypes. An
amyocarditic stain of coxsackievirus B3 (CVB3) passaged
through selenium or vitamin E-deficient mice rapidly expresses
a myocarditic genotype indicated by specific changes to the
viral genome (Beck et al., 1994, 1995). A similar finding was
observed when an attenuated strain of influenza A rapidly
gained virulence upon passage through selenium deficient mice
(Nelson et al., 2001). These results suggest dietary affects on
oxidative stress may influence viral disease progression.
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2004; Manhart et al., 2001; Micke et al., 2001; Miller et al.,
2002; Roth et al., 2002) and GSH has been shown to influence
viral replication. Glutathione levels are depressed in CD4+ T-
cells from HIV-1-infected individuals (van der Ven et al., 1998).
In vitro, HIV-1 infection of macrophages decreased GSH levels
(Garaci et al., 1997b; Staal, 1998) and intracellular GSH levels
can predict the prognosis of the disease (Herzenberg et al.,
1997). Inhibition of GSH synthesis by buthionine sulfoximine
(BSO) increased HIV yield in culture (Garaci et al., 1997b).
Influenza virus replication also has been shown to be inhibited
by GSH (Cai et al., 2003; Nencioni et al., 2003). Similarly,
HSV-1 infection in vitro caused a dramatic decrease in
intracellular GSH concentrations and addition of GSH to the
culture medium decreased viral replication by greater than 99%
(Palamara et al., 1995). Likewise, Sendai virus replication was
enhanced by BSO inhibition of GSH synthesis (Macchia et al.,
1999). Decreased plasma GSH levels correlated with increased
levels of cardiomyocyte apoptosis (Kyto et al., 2004). Few
studies, however, have examined the influence of GSH on
picornavirus replication. In this study, we examine the effect of
GSH on picornavirus replication and demonstrate that BSO
inhibits efficient viral replication by blocking formation of
mature infectious virions but does not interfere with virus-
induced cytopathic effect (CPE).
Results
Effect of BSO on GSH synthesis
BSO is a potent and specific inhibitor of GSH synthesis,
inhibiting γ-glutamyl synthase (Griffith and Meister, 1979). AFig. 1. Effect of MOI and BSO treatment on CVB3-induced CPE in HeLa-H1 cells. U
high (5.0) MOI and the development of CPE monitored. As expected, uninfected co
CVB3-infected control cells infected at an MOI of 0.5 (Panel C) or 5.0 (Panel E) exhi
exhibit CPE (Panel D). In contrast, BSO-treated cells infected at a high MOI (5.0, Pconcentration of 0.2 mM has been reported to inhibit synthesis
of glutathione (GSH) in cell culture (Hamilos and Wedner,
1985; Wullner et al., 1999). To confirm this, HeLa-H1 or L-cell
monolayers were treated with BSO for 24, 48, or 72 h. Cells
from BSO-treated or control cell monolayers were then
harvested and assayed for total glutathione (GSH+GSSG)
content (Baker et al., 1990; Tietze, 1969). BSO treatment
reduced total GSH content to undetectable levels by 48 h post-
treatment (<1% of control values; data not shown).
Effect of BSO on viral replication
Untreated or BSO-treated cell monolayers were infected
with CVB3 at a low MOI (0.5). Untreated cell monolayers
exhibited 100% CPE after approximately 18–20 h post-
infection, whereas BSO-treated monolayers were normal in
appearance (Figs. 1C and D, respectively). Cell lysates
derived from untreated monolayers contained high levels of
infectious virus (Table 1). In contrast, viral titers in cell
lysates derived from BSO-treated monolayers were near the
limit of detection (approximately 1.5 log10 TCID50/ml; Table
1). These results indicate that viral replication was inhibited
by pre-treatment of cells with BSO. Infection of a cell
monolayer at a low MOI, however, initially infects only a
fraction of the total cells present and requires release of
infectious virus to initiate secondary rounds of infection to
infect the entire monolayer. Thus, infection at a low MOI
could overestimate the degree of inhibition. To more
accurately determine the degree of viral replication in cells
treated with BSO, monolayers were infected at a high MOI
and the infections were terminated after 8–10 h; the
approximate length of time for one replication cycle.ntreated or BSO-treated Hela-H1 cells were infected with CVB3 at a low (0.5) or
ntrol (Panel A) or BSO-treated cells (Panel B) did not exhibit any signs of CPE.
bited CPE as expected but BSO-treated cells infected at a low MOI (0.5) did not
anel F) did exhibit CPE that was indistinguishable from infected control cells.
Table 1
Effect of BSO on production of infectious virus
Virus MOI Titer, control a Titer, BSO
CVB3 0.5 9.89±0.24 1.63±0.16
CVB3 5.0 9.53±0.16 3.22±0.23
CVB4 5.0 8.75±0.20 4.08±0.29
HRV14 5.0 7.31±0.19 4.42±0.29
a Values are the mean±SD of log10 transformed data from 3 to 6 replicate
cultures.
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exhibited 100% CPE and produced large amounts of infectious
virus (Table 1, Fig. 1E). BSO-treatedmonolayers infected at a high
MOI also exhibited 100% CPE but produced about 106 less
infectious virions than the control cultures (Fig. 1F, Table 1). Thus,
whereas viral-induced CPE was unaffected by BSO treatment
production of infectious virus was inhibited. All subsequent
infections were conducted at high MOIs.
To rule out the possibility that infectious virions were being
produced but became inactivated, one-step growth curves were
constructed. As the results in Fig. 2 demonstrate, large amounts
of infectious virions are produced between 4 and 6 h post-
infection in control cells and then virus production plateaus
between 6 and 10 h. In contrast, the amount of infectious virions
produced by BSO-treated cells remains at lower levels
throughout the time course and may reflect residual virus left
from the initial infection. Thus, lack of detection of infectious
virus at later time points, 8–10 h post-infection, in BSO-treated
cells does not appear to result from inactivation of virus
produced at earlier time points.
A high titer viral stock solution was treated with BSO at
2.0 mM for 1 h at room temperature to determine if BSO
directly effected virus infectivity and replication; a mock
treatment served as a control. No effect of BSO treatment on
virus infectivity was observed (data not shown). These results
indicate BSO is not directly inactivating the virus but is
affecting some aspect of viral replication.Fig. 2. One-step CVB3 growth curve in control or BSO-treated cells. Control or
BSO-treated cells were infected with CVB3 at an MOI of 5.0 and replicate
cultures were harvested at 1, 2, 3, 4, 6, 8, or 10 h post-infection. The amount of
cell-associated virus was quantified. —●—control cells; —○—BSO-treated
cells.The effect of BSO on the replication of CVB4 and human
rhinovirus 14 (HRV14) was tested to determine if BSO had a
general effect on picornavirus replication. Replication of both
CVB4 and HRV14 was inhibited by pre-treatment of cells with
BSO by approximately 4 and 3 logs, respectively (Table 1).
These results suggest that BSO inhibits replication of
picornaviruses, but results of others (Garaci et al., 1997b;
Macchia et al., 1999) indicate that BSO does not inhibit
replication of all RNA viruses.
The results suggest that GSH may be necessary for
production of infectious CVB3 because BSO is a known
specific inhibitor of GSH synthesis. This was tested by adding
GSH ethyl ester (GEE) to BSO-treated cultures. GEE is a GSH
derivative that, unlike GSH, can be readily transported across
the cell membrane and then converted to GSH via action of an
intracellular esterase (Anderson et al., 1985; Wellner et al.,
1984). Cell cultures were pre-treated with BSO and then
incubated with media containing BSO (0.2 mM) and varying
concentrations of GEE (0.5–10.0 mM) for approximately 15 h
prior to infection with CVB3. Addition of GEE to the culture
medium increased the amount of infectious virus produced in a
dose-dependent manner with 2 mM GEE restoring infectious
virus production to near control levels (Fig. 3). Thus, GSH
appears to be necessary for efficient production of infectious
picornaviruses and BSO inhibits production of infectious virus
by inhibiting GSH production.
Because GSH helps maintain the redox potential of the
cell and can serve as a reducing agent, the ability of other
reducing agents to act as surrogates for GSH was
determined. Cells were pre-treated with BSO, infected with
CVB3, and then 5 mM GEE, 2-mercaptoethanol or DTT
was added to the culture medium during and after the 1-h
virus absorption period. Neither 2-mercaptoethanol nor DTTFig. 3. Reversal of BSO-induced inhibition of infectious virion production by
glutathione ethyl ester (GEE). Control or BSO (0.2 mM)-treated HeLa cell
monolayers were co-incubated overnight with varying concentrations of GEE,
infected at an MOI of 5.0 with CVB3, and harvested 8–10 h later. The viral
titers of the resulting supernatants were measured by TCID50. Results are the
mean±SD of log10 transformed data from triplicate samples. Values were
compared using Kruskal–Wallis ANOVA on Ranks followed by Dunnett's
multiple comparison procedure. An asterisk (*) indicates that the treatment
group was significantly different from the control group; p<0.05.
Fig. 5. Effect of BSO on viral protein synthesis. Control and BSO-treated cells
were infected with CVB3 at an MOI of 5.0 and metabolically labeled with
Tran-35S-Label as described in Materials and methods. Uninfected control and
BSO-treated cells were also metabolically labeled in an identical fashion. Equal
amounts of cell lysate were subjected to SDS–PAGE on 10–20% gradient gels
and subjected to autoradiography. Lane 1—uninfected control cells; Lane 2—
uninfected BSO-treated cells; Lane 3—infected control cells; Lane 4—infected
BSO-treated cells; and Lane 5—purified mature virions.
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replication to near control levels (data not shown).
Effect of BSO on viral RNA synthesis
To determine if BSO was inhibiting viral RNA production,
control or BSO-treated HeLa cell monolayers were infected at
an MOI of approximately 5.0 and total RNA isolated 1, 2, 4, and
8 h post-infection to determine if the BSO-induced block in
production of infectious virus was due to lack of production of
positive strand RNA. Real-time PCR was used to measure the
relative amounts of viral RNA produced in the control versus
BSO-treated CVB3-infected monolayers. The amount of viral
RNA isolated from control and BSO-treated cells was not
different between the 1 and 2 h time points; however, the
amount of viral RNA increased logarithmically between 2 and
8 h (Fig. 4) but was not different between control and BSO-
treated cultures. Therefore, BSO had no effect on viral RNA
production.
Guanidine hydrochloride is a known inhibitor of the
picornavirus RNA polymerase (Caliguiri and Tamm, 1968;
Wimmer et al., 1993). Because BSO does not inhibit viral RNA
synthesis, treatment of cells with 200 μg/ml GuHCl should
inhibit viral RNA production equally in control and BSO-
treated cells. This was confirmed by measuring viral RNA
production in the presence and absence of 200 μg/ml GuHCl
and 0.2 mM BSO. Viral RNA production was virtually
abolished in both control and BSO-treated cells by treatment
with GuHCl (data not shown). Thus, the BSO block must be
occurring at a replication step that occurs after viral RNA
synthesis.
Effect of BSO on viral protein synthesis
35S-labeled proteins from cell lysates of uninfected or
CVB3-infected control or BSO-treated HeLa-H1 cell mono-
layers were separated on SDS–polyacrylamide gels. TheFig. 4. Effect of BSO treatment on viral RNA synthesis. Control or BSO-treated
cells were infected with CVB3 at an MOI of 5.0. RNA was isolated from the
cells at 1, 2, 4, or 8 h after infection, the relative amounts of viral RNA produced
measured by real-time PCR as described in Materials and methods. Viral RNA
levels in control (—●—) or BSO-treated (—○—) cells.number and intensity of labeled proteins observed in both
control and BSO uninfected cells is comparable (Fig. 5, Lanes 1
and 2, respectively). Thus, BSO treatment alone does not alter
protein synthesis in the cells to any appreciable extent.
Similarly, the number and intensity of bands appearing in
lysates from CVB3-infected cells was very similar for control
and BSO-treated cells, suggesting that viral protein synthesis
was not significantly altered by BSO treatment (Fig. 5, Lanes 3
and 4, respectively). The only clear difference was the presence
of VP2 and VP4 in infected control cultures that were not
present in BSO-treated cultures. One possible explanation for
the lack of infectious virus and the absence of VP2 and VP4 was
that only empty capsids were being produced in BSO-treated
cells.
To determine if BSO-treated cells only produced empty
capsids, the effect of BSO treatment on production of intact
infectious virions was evaluated by purifying virus from control
and BSO-treated cultures over CsCl gradients. The virus
preparation from control cells produced two prominent bands
on the CsCl gradient, the lower band in Fig. 6A, which is known
to contain infectious RNA-containing virions, and an upper
band, which contains empty capsid (Minor, 1985). In contrast,
the virus preparation from BSO-treated cells only yielded one
band corresponding in location to the upper band in the gradient
from control virus preparation. SDS–PAGE analysis of the
lower band isolated from the control virus gradient contained
viral proteins VP1–VP4, as would be expected for mature
RNA-containing virons (Fig. 6B, Lane 1). The upper band from
the control virus gradient contained viral proteins VP0, VP1,
and VP3, but no VP2 or VP4, which are formed by cleavage
within VP0 to produce mature virions (Fig. 6B, Lane 2), and is
consistent with the presence of empty capsids or other assembly
Fig. 6. Effect BSO on virion assembly. (A) CVB3 was propagated in untreated or 0.2 mM BSO-treated HeLa-H1 cells and banded on 5–40% CsCl gradients. Gradient
1—CVB3 propagated on control HeLa-H1 cells; Gradient 2—CVB3 propagated on BSO-treated HeLa-H1 cells. (B) The two bands obtained from gradient 1
(Control) and the single band obtained from gradient 2 (BSO) were isolated and examined by SDS–PAGE. MW, molecular weight markers; Lane 1, control virus
sample, band 2; Lane 2, control virus sample, band 1; Lane 3, BSO virus sample. The arrows located on the right-hand side of panel A indicate the location of viral coat
proteins VP0–VP4.
Fig. 7. Effect of BSO treatment on the levels of assembly intermediates. Control
or BSO-treated cells were metabolically labeled as described in Materials and
methods. Equal volumes of extract were fractionated over 5–20% (A) or 15–
30% (B) sucrose gradients. Gradients were fractionated from the top and
aliquots counted by liquid scintillation.
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purified BSO viral preparation, which migrated to a position
equivalent to the upper band of the control viral preparation,
produced a protein banding pattern identical to that of the upper
band from the gradient purified control virus preparation (Fig.
6B, Lane 3). Thus, in BSO-treated cells the production of
mature virions is inhibited.
Analysis of assembly intermediates
To determine if the lack of mature virions in BSO-treated
cells was due to an effect on the levels of assembly
intermediates, metabolically labeled viral proteins were sepa-
rated on sucrose gradients. Both the 5S and 14S assembly
intermediates were observed at similar concentrations in control
and BSO-treated cells (Fig. 7A). In contrast, CVB3-infected
BSO-treated cells produced a very large 75S empty capsid peak,
corresponding to the upper band observed on the CsCl
gradients, whereas a much smaller 75S peak was observed in
lysates from CVB3-infected control cells (Fig. 7B). Further-
more, whereas a 150S mature virion peak was observed in
gradients from CVB3-infected control cells, no 150S peak was
seen in lysates derived from infected BSO-treated cells, again in
agreement with results obtained from the CsCl gradients. No
other peaks of intermediate size were observed. The composi-
tion of the 5S, 14S, 75S, and 150S peaks were confirmed by
analysis of peak fractions by SDS–PAGE and the results are
shown in Fig. 8 and are consistent with each of the various
assembly intermediates and mature virions. Therefore, these
results indicate that BSO treatment of cells results in increased
Fig. 8. Protein composition of assembly intermediates. Aliquots from the peak
fractions corresponding to the 5S, 14S, and 75S assembly intermediates, the
150S mature virion peak, and the corresponding fraction from the BSO 15–30%
gradient were subjected to SDS–PAGE and autoradiography. The letters B and
C denote fractions derived from BSO-treated and control cultures, respectively.
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mature virions.
Discussion
The results presented here demonstrate that GSH is required
for efficient production of infectious virions because viral
replication was inhibited by BSO, a specific GSH synthesis
inhibitor. Further evidence that the inhibition of viral replication
is GSH specific was demonstrated by the reversal of inhibition
by GSH ethyl ester, a GSH analog that can be transported across
the cell membrane and then converted into free GSH (Anderson
et al., 1985; Wellner et al., 1984). The reversal was dose
dependent with approximately 2 mM GEE required to fully
recover infectivity. Other sulfhydryl reagents such as 2-
mercaptoethanol and dithiothreitol were not effective at
restoring production of infectious virions. The reasons for this
are not clear as both 2-mercaptoethanol and dithiothreitol are
able to cross the plasma membrane. 2-Mercaptoethanol crosses
as a mixed disulfide (Ishii et al., 1981) whereas dithiothreitol
(DTT) can freely cross the membrane itself (Lauriault and
O'Brien, 1991). Both DTT and 2-mercaptoethanol have been
reported to protect cell line from BSO-induced cell death (Chen
et al., 1987; Wang et al., 2006), suggesting that they can
substitute for GSH in some intracellular functions.
The results presented here for picornaviruses contrast with
those obtained with HIVand Sendai virus where BSO treatment
increased virus replication (Garaci et al., 1997a; Macchia et al.,
1999). Increased HIV replication likely occurs via reactive
oxygen species activation of NF-κB but a mechanism of action
on Sendai virus replication is not known. Influenza replication is
inhibited by GSH and is enhanced when GSH levels are reduced
(Cai et al., 2003). Inhibition of influenza infection by GSH
appears to occur via GSH-dependent inhibition of apoptosis (Cai
et al., 2003) which may slow virus release.Production of infectious virus was not due to lack of viral
RNA synthesis. Real-time PCR measurement of RNA produc-
tion indicated that equivalent levels of viral RNA were being
produced in control and BSO-treated cells that were equally
inhibited by GuHCl. Viral protein synthesis also was unaffected
by BSO treatment as evidenced by the comparable production
of radiolabeled viral proteins in control and BSO-treated cells.
This indicates that processing of the viral polyprotein P1, by
viral proteases 2A and 3C (or 3CD), is occurring normally or
the distribution of viral protein products would be altered. In
addition, because viral RNA production is unaffected by BSO
treatment the viral polymerase, 3D, and VPg, both required for
viral RNA synthesis, must be functional.
Assembly of infectious virions, however, does appear to be
inhibited in BSO-treated cells. Cell lysates from CVB3-infected
BSO-treated cells purified over CsCl gradients did not yield a
band corresponding to mature infectious particles but only a band
corresponding to empty capsids. Further analysis of infected
control or BSO-treated cell lysates by fractionation on sucrose
gradients revealed that BSO treatment did not alter the
concentration of the 5S and 14S assembly intermediates but
produced higher levels of the 75S empty capsids at the expense
of mature 150S virion production. Nor was a 110S peak
observed as was seen in hydantoin-treated cultures (Vance et al.,
1997), a drug that also inhibited replication but did not interfere
with viral RNA synthesis or translation. Previous studies have
linked the production of large amounts of empty capsids with
decreased viral RNA synthesis, arguing for a tight coupling
between viral RNA synthesis and RNA packaging (Baltimore et
al., 1966; Caliguiri and Compans, 1973; Hellen and Wimmer,
1995) and that empty capsids may be dead-end particles
(Verlinden et al., 2000). The results presented here suggest that
viral RNA synthesis can be decoupled from the production of
mature RNA-containing virions and that BSO treatment produces
a defect in infectious virion assembly. This suggests that
glutathione itself or a glutathione-dependent process is required
for efficient encapsidation of viral RNA to produce infectious
virions. Glutathione is a potent intracellular reductant and lack of
glutathione may promote a pro-oxidant environment within the
cell. Thus, it may be that a reducing environment is needed for a
critical step in production of mature RNA-containing virions
although two other sulfhydryl reducing agents, 2-mecaptoethanol
and dithiothreitol, could not substitute for glutathione, indicating
the specificity of the glutathione effect.
Although BSO substantially reduced infectious virion
production in HeLa cells in vitro, it did not interfere with
induction of viral-induced CPE. This became apparent,
however, only in cultures infected at a high MOI where all of
the cells are infected during the virus adsorption step. The cell
sheet remained intact in cultures infected at a low MOI due to
lack of secondary rounds of infection. A study by Mikami et al.
(2004) reported that BSO inhibited Echovirus 9-induced CPE in
green monkey kidney cells. These investigators, however, only
infected cells at a very low MOI of approximately 0.01, thus
initially infecting only a very small percentage of the cells under
conditions in which secondary rounds of infection would be
inhibited.
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the absence of infectious virion production is likely due to the
fact that viral protein synthesis is not altered by BSO treatment.
Induction of CPE has been shown to be dependent on
productive infections and treatment with drugs such as
GuHCl, which inhibits viral RNA synthesis and therefore
viral protein synthesis, favor the apoptotic pathway (Agol et al.,
1998, 2000; Rasilainen et al., 2004; Tolskaya et al., 1995). Viral
proteins with pro and anti-apoptotic properties have been
identified including VP2, 2A, 2B, 2BC, and 3A (Buenz and
Howe, 2006; Goldstaub et al., 2000; Henke et al., 2001; Salako
et al., 2006). In productive infections, when viral protein
expression is high, especially in the later stages of the viral
replication cycle, CPE is favored over apoptosis (Agol et al.,
2000; Romanova et al., 2005). Therefore, it seems likely that the
CPE observed in BSO-treated cells is due to the normal
synthesis and function of viral proteins even though mature
virions are not produced.
The results presented here indicate that GSH is necessary for
efficient production of infectious virions. Viral RNA and
protein synthesis are not affected by BSO treatment, but proper
encapsidation of viral RNA and the maturation cleavage step
that is characteristic of mature infectious virions production is
affected. These results also indicate that induction of viral-
induced CPE is not dependent on efficient production of
infectious virions.
Materials and methods
Cells and virus
Hela-H1 cells were grown as monolayers in minimal
essential medium (MEM, Gibco cat. # 11090-081) supplemen-
ted with L-glutamine to 2 mM, non-essential amino acids to
0.1 mM, penicillin-streptomycin to 100 U/ml, and 5% fetal
bovine serum (Complete medium). Stocks of coxsackievirus
B3/0 (CVB3), an amyocarditic CVB3 strain (Chapman et al.,
1994), coxsackievirus B4 (CVB4), and human rhinovirus 14
(HRV14) were prepared in Hela-H1 cells (Sherry and Rueckert,
1985).
Infectivity assays
For CVB3, CVB4, and HRV14, viral titers in tissue culture
supernatants were assayed on HeLa-H1 cells by tissue culture
infectious dose (TCID)50. One hundred microliters of 10-fold
serial dilutions of samples was mixed with 100 μL of cell
suspension containing 1.0E+04 cells in 96-well tissue culture
plates. Six replicates of each dilution were plated and allowed to
incubate for three days at 37 °C and 5% CO2. Wells were
visually scored for virus growth and the TCID50 calculated
(Lynn, 1992).
Cell treatments
Hela-H1 or L-cells were propagated for a minimum of 48 h
in the presence of 0.2 mM L-buthionine-S,R-sulfoximine (BSO)prior to use in experiments, when GSH levels had been reduced
to undetectable levels (Baker et al., 1990; Tietze, 1969). Cells
were infected either with a low multiplicity of infection (MOI),
0.5, or a high MOI, 5.0–10.0, for 1 h. In all experiments, the
cells were washed extensively after the virus absorption step to
remove unbound virus. Control and BSO-treated cell cultures
infected at a low MOI were allowed to progress for
approximately 16–20 h; a time when cultures without BSO
treatment were at 100% CPE. In some experiments, glutathione
ethyl ester (GEE) was added to BSO-treated cultures at 0.5, 1.0,
2.0 5.0, or 10 mM in addition to BSO at 0.2 mM and incubated
overnight prior to and during subsequent infection with CVB3.
In other experiments, BSO-treated cultures were also treated
with GEE, 2-mercaptoethanol, or dithiothreitol at 5 mM during
and after the initial 1-h virus absorption step. For the one-step
growth curve, replicate cultures were infected at an MOI of 5
and at 1, 2, 3, 4, 6, 8, or 10 h post-infection, the growth medium
removed and the amount of cell associated virus was quantified
as described above.
Quantitation of viral RNA
Control or BSO-treated (0.2 mM) cell monolayers were
infected with CVB3 at an MOI of 5 and incubated for 1, 2, 4,
and 8 h post-infection. The cell monolayers were washed with
PBS to remove residual tissue culture medium and the RNAwas
extracted using Trizol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer's instructions (Solano-Aguilar
et al., 2002), and then treated with RNase free DNase. RNA
integrity, quantity, and detection of genomic DNA was
determined using the Agilent Bioanalyzer 2100 and RNA
6000 Labchip kit (Agilent Technologies, Palo Alto, CA). cDNA
was synthesized using Improm-II Reverse Transcriptase System
(Promega, Madison, WI) and random primers. Twenty-five
nanograms of cDNA/reaction was then used for PCR
amplification using a commercially available kit and amplifica-
tion was measured on an ABI Prism 7700 Sequence Detector
System (Applied Biosystems, Foster City, CA). The probes
were 5′ TET (tetrachloro-6-carboxyfluoroscein) labeled and 3′
BHQ1 (Black Hole 1) labeled and were synthesized by
Biosource International (Camarillo, CA). VIC- and TAMRA
(6-carboxy-tetramethyl-rhodamine)-labeled internal oligonu-
cleotide probe and primers specific for the 18S RNA ribosomal
subunit were purchased from Applied Biosystems (Foster City,
CA). Fluorescence signals measured during amplification were
processed post-amplification and were regarded as positive if
the fluorescence intensity was 20-fold greater than the standard
deviation of the baseline fluorescence. This level is defined as
the threshold cycle (Ct). Viral RNA levels were normalized to
18S RNA. The Ct value for 18S ribosomal subunit was
subtracted from the Ct value for each message to normalize for
eukaryotic RNA content. This value is defined as ΔCt. To
evaluate the effects of treatment, the mean of ΔCttreatment was
subtracted from the mean of ΔCtcontrol. This value is defined as
ΔΔCt. The relative fold increase or decrease was then
calculated as 2−ΔΔCt (Livak and Schmittgen, 2001). To assess
the affect of guanidine hydrochloride (GuHCl) treatment on
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added after the initial 1 h virus absorption step. One set of
control and BSO-treated cultures was harvested after the virus
absorption and washing steps to determine the baseline viral
RNA levels prior to GuHCl treatment. Viral RNA was isolated
from the remaining cultures at 8 h post-infection. Total RNA
from one set of cultures was harvested immediately after the
virus absorption and washing steps to serve as a baseline for
viral RNA production prior to GuHCl treatment.
Metabolic labeling of viral proteins
HeLa-H1monolayers±BSO (4.0×106 cells) were infected at an
MOI of 5.0. After a 1-h absorption period, cells were fed with
complete medium. At 3.5 h post-infection, the monolayers were
washed with D–PBS and then Dulbecco's modified Eagle medium
(DMEM, Invitrogen cat. # 21013-024) without methionine or
cysteine (cystine) but supplemented with L-glutamine to 2 mM,
non-essential amino acids to 0.1 mM, penicillin-streptomycin to
100U/mlwas added. At 4 h post-infection, 30μCi/ml of Trans-35S-
Label (>1000 Ci/mmol, MP Biomedicals, Inc.) was added. At 6 h
post-infection, the media were removed, the monolayers washed
one time with D–PBS, and the cells lysed by addition of 10 mM
Tris–HCL, pH 7.5, 10 mMNaCl, 1.5 mMMgCl2 containing 0.1%
NP-40 and frozen at −80 °C. After thawing, the cellular debris was
removed by centrifugation for 3min at 16,000×g. Equal volumes of
cell lysate were subjected to SDS–PAGE on 10–20% gels. The
resulting gels were dried and exposed to Biomax MR-1 film
(Kodak).
Purification of virus
Untreated or BSO-treated HeLa-H1 monolayers were
infected with CVB3 at an MOI of approximately 5.0 and
incubated 8–10 h. When CPE became apparent, the medium
was removed and the plates frozen. Virus was released from the
cells by 3 rounds of freeze/thaw and the resulting cell lysate was
clarified by centrifugation. The clarified supernatant was DNase
treated, and N-lauryl-sarcosine added to 1.0%. The resulting
supernatant was overlaid onto a 10-mM Tris, pH 7.4, 30%
sucrose cushion and centrifuged at 110,000×g for 130 min in a
Ti70 rotor. The resulting pellets were dissolved in 10 mM Tris,
0.15 M NaCl, pH 7.4. The concentrated virus was then layered
onto 5–40% CsCl (wt/wt) gradients and centrifuged in an SW41
rotor at 100,000×g for 7 h. The gradients were fractionated.
Fractions containing the upper and lower bands from the
gradients were diluted with 10 mM Tris, 0.15 M NaCl, pH 7.4,
and concentrated by ultracentrifugation. The resulting pellets
were redissolved in 10 mM Tris, 0.15 M NaCl, pH 7.4, and the
protein concentration of the samples was determined using the
BCA Protein Assay (Pierce, Chicago, IL).
Analysis of assembly intermediates by sucrose gradient
fractionation
HeLa-H1 monolayers±BSO (8–12×107 cells) were infected
at an MOI of 5.0 and metabolically labeled as described aboveusing 10 μCi/ml of label. One milliliter of the resulting
supernatants was layered on top of linear 5–20% (wt/vol) or
15–30% (wt/vol) sucrose gradients. Gradients (15–30%
gradients) were centrifuged at 38,000 rpm in a Beckman
SW41 rotor for 2.5 h at 4 °C or 37,000 rpm for 17 h (5–20%
gradients). Gradients were fractionated from the top and the
radioactivity in each fraction (approximately 350 μl) was
quantified by liquid scintillation. Samples from the peak
fractions were analyzed by SDS–PAGE and autoradiography.
Samples for SDS–PAGE were mixed with a loading buffer to
give a final concentration of 68.5 mM Tris pH 6.8, SDS and 2-
mercaptoethanol of 2%, and 10% glycerol and were heated at
100 °C for 5 min. Equal volumes of lysates or peak fractions
were analyzed.
Total glutathione determination
Cell monolayers were washed with D–PBS without Mg or
Ca to remove residual medium and treated with a trypsin/EDTA
solution to liberate the cells. Cells were then collected by
centrifugation and resuspended in D–PBS without Mg or Ca.
An aliquot was taken to determine the cell concentration.
Remaining cells were collected by centrifugation and resus-
pended in 50 μl of D–PBS and 200 μl of 5% sulfosalicylic acid
added. The samples were centrifuged to remove cellular debris
and the resulting supernatant stored at −80 °C until assayed.
Glutathione is stable for 12 months in samples prepared in 5%
sulfosalicylic acid and stored at −80 °C (Roberts and Francetic,
1993). Samples were assayed for GSH using a modification of
the Tietze (1969) recycling method adapted for use in 96-well
plates (Baker et al., 1990).
Statistical analyses
Data were analyzed by one or two-way ANOVAwith a post
hoc multiple comparisons analysis using the Student–Neuman–
Keuls or Dunnett's method. Data were transformed as necessary
to pass the normality and equal variance tests for statistical
analysis or an ANOVA was performed on Ranks. A p value of
less than 0.05 was considered significant.
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